Abstract
To date, the skin remains the most common cancer site among Caucasians in the western world. The complex, layered structure of human skin harbors a heterogenous population of specialized cells. Each cell type residing in the skin potentially gives rise to a variety of cancers, including non-melanoma skin cancer, sarcoma, and cutaneous melanoma. Cutaneous melanoma is known to exacerbate and metastasize if not detected at an early stage, with mutant melanomas tending to acquire treatment resistance over time. The intricacy of melanoma thus necessitates diverse and patient-centered targeted treatment options. In addition to classical treatment through surgical intervention and radio- or chemotherapy, several systemic and intratumoral immunomodulators, pharmacological agents (e.g., targeted therapies), and oncolytic viruses are trialed or have been recently approved. Moreover, utilizing combinations of immune checkpoint blockade with targeted, oncolytic, or anti-angiogenic approaches for patients with advanced disease progression are promising approaches currently under pre-clinical and clinical investigation. In this review, we summarize the current ‘state-of-the-art’ as well as discuss emerging agents and regimens in cutaneous melanoma treatment.
Reference124 articles.
1. Age-Specific Incidence of Melanoma in the United States
2. Epidemiological trends in skin cancer
3. Vital signs: Melanoma incidence and mortality trends and projections—United States, 1982–2030;Guy;MMWR Morb. Mortal. Wkly. Rep.,2015
4. Skin Cancer Facts and Statistics. Skin Cancer Information. Last Updated: January 13, 2021https://www.skincancer.org/skin-cancer-information/skin-cancer-facts/
5. Public primary and secondary skin cancer prevention, perceptions and knowledge: an international cross-sectional survey
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献